How should sertraline (Zoloft) be monitored in patients aged 65 and older, including baseline labs, vital signs, hyponatremia screening, orthostatic hypotension, falls, mental status, and drug interactions?

Monitoring Sertraline (Zoloft) in Geriatric Patients

Monitor serum sodium within the first 2 weeks of initiating sertraline in patients ≥65 years, as the risk of profound hyponatremia is highest during this period, with an adjusted odds ratio of 10.06 in the first 2 weeks, declining to 4.29 at 3 months 1. This risk is particularly pronounced in women ≥80 years (6.5% incidence) compared to men of the same age (3.4% incidence) 1.

Baseline Assessment

Before initiating sertraline:

• Serum sodium level - Essential baseline given the 3-4% incidence of profound hyponatremia in patients ≥65 years 1
• Blood pressure (seated and standing) - Measure orthostatic vital signs to establish baseline, as older adults have increased risk of orthostatic hypotension 2
• Renal function - No dose adjustment needed for renal impairment, but baseline creatinine helps contextualize future changes 3
• Hepatic function - Patients with mild hepatic impairment (Child-Pugh 5-6) require 50% dose reduction due to 3-fold increased exposure 3
• Current medication review - Identify drugs that increase hyponatremia risk (diuretics, NSAIDs) or interact via CYP2D6 inhibition 3

Ongoing Monitoring Schedule

Weeks 1-2 (Highest Risk Period)

• Serum sodium: Check at 1-2 weeks post-initiation, when hyponatremia risk peaks (OR 10.06) 1
• Mental status: Monitor for confusion, lethargy, or altered cognition suggesting hyponatremia 4
• Orthostatic blood pressure: Assess at each visit, though RCTs show intensive BP control does not exacerbate orthostatic hypotension 2

Weeks 3-12

• Serum sodium: Recheck at 4 weeks and 12 weeks, as risk remains elevated (OR 4.29 at 3 months) 1
• Falls assessment: Document any falls, though sertraline did not significantly increase fall risk in RCT data (OR 1.56,95% CI 0.63-3.83) 5
• Weight monitoring: Track weight as SSRIs can cause appetite changes 3

Beyond 3 Months

• Serum sodium: Monitor every 3-6 months, as risk normalizes after 1 year (OR 1.30) 1
• Clinical response: Assess depressive symptoms and tolerability

High-Risk Populations Requiring Intensified Monitoring

Patients with the following characteristics need more frequent sodium checks (weekly for first month):

• Female gender - Women ≥80 years have 6.5% incidence of profound hyponatremia vs 3.4% in men 1
• Concurrent diuretic use - Synergistic risk for hyponatremia 6
• Low baseline sodium (<135 mmol/L) - Predicts higher risk 6
• Low body weight - Independent risk factor 6
• Age ≥80 years - 4% overall incidence of profound hyponatremia 1

Drug Interactions Requiring Monitoring

• CYP2D6 substrates: Sertraline inhibits CYP2D6, increasing levels of co-administered drugs metabolized by this pathway 3
• Pimozide: Contraindicated - sertraline increases pimozide AUC by 40% with QTc prolongation risk 3
• NSAIDs: Monitor for acute kidney injury and increased bleeding risk 3
• Warfarin: Exercise caution if levels near upper therapeutic limit 3

Management of Hyponatremia

When sodium <125 mmol/L develops:

1. Discontinue sertraline immediately - Hyponatremia typically resolves within 2 weeks of discontinuation 6
2. Implement water restriction for isovolemic hypotonic hyponatremia 6
3. Consider loop diuretic for mild diuresis 6
4. Severe cases: Use higher-dose loop diuretics with hypertonic saline 6

Critical Caveats

• Do not assume age alone contraindicates treatment: The FDA label notes no overall safety differences between elderly and younger patients in clinical trials 3
• Start at 25-50 mg daily: Use lower starting doses in elderly patients, though no formal age-based dose adjustment is required 3
• Avoid moderate-severe hepatic impairment: Use is not recommended in Child-Pugh scores ≥7 due to lack of safety data 3
• Rechallenge risk: Limited data exist on rechallenge after hyponatremia; some patients redevelop hyponatremia with same or different SSRIs 6

The evidence consistently demonstrates that sertraline-induced hyponatremia is time-dependent, with the highest risk in the first 2 weeks 1, making early sodium monitoring non-negotiable in geriatric patients. While comparative data suggest sertraline may have lower hyponatremia risk than duloxetine or escitalopram 7, 8, the absolute risk remains clinically significant in elderly populations, particularly women ≥80 years.